Cargando…
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the sixth most common cancer in the US. However, no significant changes in management have occurred since the tyrosine kinase era until the recent breakthrough with checkpoint inhibitors. Therefore, the need for more therapeutic options is paramount. Our objective was t...
Autores principales: | Pletcher, Jerred P., Bhattacharjee, Sayani, Doan, Jonathan P., Wynn, Rebecca, Sindhwani, Puneet, Nadiminty, Nagalakshmi, Petros, Firas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300201/ https://www.ncbi.nlm.nih.gov/pubmed/34307148 http://dx.doi.org/10.3389/fonc.2021.681441 |
Ejemplares similares
-
Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021) -
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
por: Bhattacharjee, Sayani, et al.
Publicado: (2022) -
Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
por: Sha, Huanhuan, et al.
Publicado: (2021) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)